Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. TSLA
9. BRZE
10. GOOGL

Go back to Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

October 12, 2026 12:06 PM EDT

Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP

Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control

TARRYTOWN, N.Y., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). These longer-term findings for Pasatru... More